A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME-Reference-Cited by-同舟云学术

A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME

Published:2022-07 Issue: Volume:181 Page:106269
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Xiao Xuejun,Peng Yan,Wang Zheyue,Zhang Louqian,Yang Tingting,Sun Yangyang,Chen Yufeng,Zhang Wenqing,Chang Xinxia,Huang Wen,Tian Shuning,Feng Zhenqing,Xinhua Nabi,Tang Qi,Mao Yuan

Publisher

Elsevier BV

Subject

Pharmacology

Reference61 articles.

1. Cancer statistics, 2021;Siegel;CA Cancer J. Clin.,2021

2. Quaking 5 suppresses TGF-beta-induced EMT and cell invasion in lung adenocarcinoma;Wang;EMBO Rep.,2021

3. Non-genetic evolution drives lung adenocarcinoma spatial heterogeneity and progression;Tavernari;Cancer Discov.,2021

4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

5. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies;Nosaki;Lung Cancer,2019

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma;The Clinical Respiratory Journal;2024-05

2. Identifying the tumor-associated macrophage of lung adenocarcinoma reveals immune landscape through omics data integration;Heliyon;2024-03

3. Exploration of the prognostic prediction value of the PANoptosis‐based risk score and its correlation with tumor immunity in lung adenocarcinoma;The Journal of Gene Medicine;2024-03

4. Identification of the novel biomarkers involved in the mitochondrial metabolism-related reactive oxygen species and their role in lung cancer T-cell exhaustion and immunotherapy;Heliyon;2024-03

5. Targets of tumor microenvironment for potential drug development;MedComm – Oncology;2024-03